Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study

Satoshi Iraha,1–5 Yasuhiko Hirami,1,2 Sachiko Ota,1,2 Genshiro A Sunagawa,3 Michiko Mandai,1–3 Hidenobu Tanihara,5 Masayo Takahashi,1–4 Yasuo Kurimoto1,2 1Department of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, 2Departme...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Iraha S, Hirami Y, Ota S, Sunagawa GA, Mandai M, Tanihara H, Takahashi M, Kurimoto Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	retinitis pigmentosa valproic acid clinical trial retina Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/b6dd3044a84d4574a3445b30818c6d63
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b6dd3044a84d4574a3445b30818c6d63
record_format	dspace
spelling	oai:doaj.org-article:b6dd3044a84d4574a3445b30818c6d632021-12-02T04:59:09ZEfficacy of valproic acid for retinitis pigmentosa patients: a pilot study1177-5483https://doaj.org/article/b6dd3044a84d4574a3445b30818c6d632016-07-01T00:00:00Zhttps://www.dovepress.com/efficacy-of-valproic-acid--for-retinitis-pigmentosa-patients-a-pilot-s-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Satoshi Iraha,1–5 Yasuhiko Hirami,1,2 Sachiko Ota,1,2 Genshiro A Sunagawa,3 Michiko Mandai,1–3 Hidenobu Tanihara,5 Masayo Takahashi,1–4 Yasuo Kurimoto1,2 1Department of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, 2Department of Ophthalmology, Kobe City Medical Center General Hospital, 3Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, 4Application Biology and Regenerative Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 5Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan Purpose: The purpose of this study was to examine the efficacy and safety of valproic acid (VPA) use in patients with retinitis pigmentosa (RP).Patients and methods: This was a prospective, interventional, noncomparative case study. In total, 29 eyes from 29 patients with RP whose best-corrected visual acuities (BCVAs) in logarithm of the minimum angle of resolution (logMAR) ranged from 1.0 to 0.16 with visual fields (VFs) of ≤10° (measured using Goldmann perimeter with I4) were recruited. The patients received oral supplementation with 400 mg of VPA daily for 6 months and were followed for an additional 6 months. BCVAs, VFs (measured with the Humphrey field analyzer central 10-2 program), and subjective questionnaires were examined before, during, and after the cessation of VPA supplementation.Results: The changes in BCVA and VF showed statistically significant differences during the internal use of VPA, compared with after cessation (P=0.001). With VPA intake, BCVA in logMAR significantly improved from baseline to 6 months (P=0.006). The mean deviation value of the VF significantly improved from baseline to 1 month (P=0.001), 3 months (P=0.004), and 6 months (P=0.004). These efficacies, however, were reversed to the baseline levels after the cessation of VPA intake. There were no significant relations between the mean blood VPA concentrations of each patient and the changes in BCVA and VF. During the internal use of VPA, 15 of 29 patients answered “easier to see”, whereas blurred vision was registered in 21 of 29 patients on cessation. No systemic drug-related adverse events were observed.Conclusion: While in use, oral intake of VPA indicated a short-term benefit to patients with RP. It is necessary to examine the effect of a longer VPA supplementation in a controlled study design. Keywords: retinitis pigmentosa, valproic acid, clinical trial, retinaIraha SHirami YOta SSunagawa GAMandai MTanihara HTakahashi MKurimoto YDove Medical Pressarticleretinitis pigmentosavalproic acidclinical trialretinaOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 1375-1384 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	retinitis pigmentosa valproic acid clinical trial retina Ophthalmology RE1-994
spellingShingle	retinitis pigmentosa valproic acid clinical trial retina Ophthalmology RE1-994 Iraha S Hirami Y Ota S Sunagawa GA Mandai M Tanihara H Takahashi M Kurimoto Y Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study
description	Satoshi Iraha,1–5 Yasuhiko Hirami,1,2 Sachiko Ota,1,2 Genshiro A Sunagawa,3 Michiko Mandai,1–3 Hidenobu Tanihara,5 Masayo Takahashi,1–4 Yasuo Kurimoto1,2 1Department of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, 2Department of Ophthalmology, Kobe City Medical Center General Hospital, 3Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, 4Application Biology and Regenerative Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 5Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan Purpose: The purpose of this study was to examine the efficacy and safety of valproic acid (VPA) use in patients with retinitis pigmentosa (RP).Patients and methods: This was a prospective, interventional, noncomparative case study. In total, 29 eyes from 29 patients with RP whose best-corrected visual acuities (BCVAs) in logarithm of the minimum angle of resolution (logMAR) ranged from 1.0 to 0.16 with visual fields (VFs) of ≤10° (measured using Goldmann perimeter with I4) were recruited. The patients received oral supplementation with 400 mg of VPA daily for 6 months and were followed for an additional 6 months. BCVAs, VFs (measured with the Humphrey field analyzer central 10-2 program), and subjective questionnaires were examined before, during, and after the cessation of VPA supplementation.Results: The changes in BCVA and VF showed statistically significant differences during the internal use of VPA, compared with after cessation (P=0.001). With VPA intake, BCVA in logMAR significantly improved from baseline to 6 months (P=0.006). The mean deviation value of the VF significantly improved from baseline to 1 month (P=0.001), 3 months (P=0.004), and 6 months (P=0.004). These efficacies, however, were reversed to the baseline levels after the cessation of VPA intake. There were no significant relations between the mean blood VPA concentrations of each patient and the changes in BCVA and VF. During the internal use of VPA, 15 of 29 patients answered “easier to see”, whereas blurred vision was registered in 21 of 29 patients on cessation. No systemic drug-related adverse events were observed.Conclusion: While in use, oral intake of VPA indicated a short-term benefit to patients with RP. It is necessary to examine the effect of a longer VPA supplementation in a controlled study design. Keywords: retinitis pigmentosa, valproic acid, clinical trial, retina
format	article
author	Iraha S Hirami Y Ota S Sunagawa GA Mandai M Tanihara H Takahashi M Kurimoto Y
author_facet	Iraha S Hirami Y Ota S Sunagawa GA Mandai M Tanihara H Takahashi M Kurimoto Y
author_sort	Iraha S
title	Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study
title_short	Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study
title_full	Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study
title_fullStr	Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study
title_full_unstemmed	Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study
title_sort	efficacy of valproic acid for retinitis pigmentosa patients: a pilot study
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/b6dd3044a84d4574a3445b30818c6d63
work_keys_str_mv	AT irahas efficacyofvalproicacidforretinitispigmentosapatientsapilotstudy AT hiramiy efficacyofvalproicacidforretinitispigmentosapatientsapilotstudy AT otas efficacyofvalproicacidforretinitispigmentosapatientsapilotstudy AT sunagawaga efficacyofvalproicacidforretinitispigmentosapatientsapilotstudy AT mandaim efficacyofvalproicacidforretinitispigmentosapatientsapilotstudy AT taniharah efficacyofvalproicacidforretinitispigmentosapatientsapilotstudy AT takahashim efficacyofvalproicacidforretinitispigmentosapatientsapilotstudy AT kurimotoy efficacyofvalproicacidforretinitispigmentosapatientsapilotstudy
_version_	1718400913133010944

Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study

Ejemplares similares